WillItSurvive
Pharma and healthcare groups · South Korea

Celltrion

celltrion.com ↗

South Korean maker of biosimilar copies of biologic drugs like Remicade and Humira.

Defensible for now
Assessed 25 July 2026 · Evidence as of 25 July 2026
Real protection, with named pressure against it.
On the recordSince 25 July 2026 · Checkable from Q4 2026 · Every call on the record Checkpoint: Zymfentra 2H 2026 US prescription growth data and progress toward the KRW 5.3T 2026 revenue target
The call

Celltrion sells at scale and profit today on approvals and payer contracts that peers cannot instantly copy, while those same peers pile onto its molecules one by one.

Celltrion is a South Korean company that makes biosimilar drugs, which are cheaper versions of expensive brand-name biologics. The company has strong profits and FDA approval to sell these drugs in the US, plus agreements with many insurance companies to cover them. It is hard to copy these drugs because they require FDA approval, huge manufacturing plants, and insurance deals, but Celltrion's biggest problem is that Samsung Bioepis, Sandoz, Amgen, and other well-funded companies are already selling or launching the exact same cheaper copies of the same drugs, which pushes prices down. The one thing that could change everything is whether Celltrion can keep growing its bestselling drug Zymfentra faster than its competitors launch their versions, and whether it wins or loses a patent fight with Regeneron over the drug Eylea.

Why
01
AI pressure: None apparent. AI tools speed internal drug design and factory robotics but cannot substitute for FDA approval, GMP plants, or payer contracts. Could AI do the core job? Unlikely.
02
Bigger players: Samsung Bioepis/Sandoz, Amgen, Biocon, Formycon. Rivals already sell competing biosimilars on the same molecules: denosumab has 5+ competitors, ustekinumab faces Pyzchiva. Could a giant copy it? Probably.
03
What protects it. FDA interchangeability status, GMP manufacturing scale, and over 90% US payer coverage on Zymfentra lock in prescribers and pharmacies.
What would change this call
Zymfentra US prescription growth rate reported for Q2-Q4 2026. A drop below roughly 40% YoY would show Celltrion's key US growth driver losing momentum.
Outcome of Regeneron's Eylea (aflibercept) '865 patent litigation against Celltrion. An adverse ruling would block or delay Celltrion's US aflibercept biosimilar launch.
Celltrion's reported full-year 2026 revenue versus its KRW 5.3 trillion guidance. A miss of more than 15% would indicate biosimilar price competition is outpacing its cost advantages.
Key numbers
  • FY2025 revenue KRW 4.1625T, up 17% YoY (2026-02-05)
  • Zymfentra US prescriptions up 185% YoY in Q1 2026 (2026-05-21)
  • Zymfentra covered by over 90% of US insurance market (2026-03-18)
Named risks
  • Adverse ruling in Regeneron Eylea (aflibercept) patent MDL could delay biosimilar commercialization. Severity: high
  • Peer biosimilar launches (Samsung Bioepis/Sandoz, Amgen, Biocon) erode pricing and formulary share on shared molecules. Severity: medium
  • 2026 guidance of KRW 5.3 trillion revenue may be missed given its aggressive step-up from 2025's KRW 4.1625T. Severity: medium
  • Unproven execution risk on new Branchburg NJ CDMO plant and Eli Lilly contract ramp. Severity: medium
  • Internal governance friction: 70.4% shareholder opposition to Celltrion Pharm merger and first union formed June 2026. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Samsung Bioepis/SandozcontestingMarch 2026 deal to co-commercialize up to 5 more biosimilars, including Entyvio biosimilar
AmgencontestingDenosumab patent suit settled via consent judgment April 2025; both compete on Prolia/XGEVA biosimilars
RegeneroncontestingEylea aflibercept patent MDL ongoing, key '865 patent not expiring until 2027
Biocon BiologicscontestingCompeting biosimilar maker active on denosumab and other shared molecules
Questions people ask
Is Celltrion profitable in 2026?
Yes. Celltrion reported FY2025 operating profit of KRW 1.1685 trillion (about $794M), up 137.5% YoY, on revenue of KRW 4.1625 trillion, up 17% YoY, per its February 5, 2026 earnings release, its first year topping KRW 4T revenue and KRW 1T operating profit.
Who owns Celltrion?
Celltrion, Inc. (KRX:068270) is publicly traded. Founder Seo Jung-jin controls the group via Celltrion Holdings Co., where he holds about 97-98% as of January 2026; Celltrion Holdings in turn owns roughly 21.6-23% of Celltrion, Inc. following the December 2023 merger with Celltrion Healthcare.
Could AI replace Celltrion?
No. Celltrion's moat is FDA/EMA biosimilar and interchangeability approvals, GMP manufacturing scale, and payer formulary lock-in (over 90% US coverage for Zymfentra as of March 2026). Its May 2026 'AX' initiative uses AI for R&D and factory automation but cannot substitute for regulatory approval or payer contracts.
Who is Celltrion's biggest competitor?
Samsung Bioepis, partnered with Sandoz, is Celltrion's closest biosimilar rival, striking a deal in March 2026 covering up to five more biosimilar assets. Amgen, Biocon, and Formycon also compete on the same reference molecules such as denosumab and ustekinumab.
Is Celltrion's Zymfentra a success in the US?
Yes. Zymfentra (Remsima SC) US prescriptions grew 185% YoY in Q1 2026, and Celltrion USA subsidiary revenue roughly doubled from KRW 146.7B in 2024 to KRW 304.9B in 2025, with over 90% US insurance payer coverage as of March 2026.
What is Celltrion's 2026 revenue target?
Celltrion set a 2026 revenue guidance of KRW 5.3 trillion, announced with its February 5, 2026 record FY2025 results (KRW 4.1625 trillion revenue). This is company guidance and has not yet been independently verified against actual 2026 results.
Timeline
  • 2026-06Celltrion's first employee union formed
  • 2026-05-25Company-wide AI Transformation (AX) initiative announced, targeting up to 90% cut in work hours
  • 2026-05-21Reports show Celltrion USA revenue nearly doubled to KRW 304.9B in 2025
  • 2026-03-18Samsung Bioepis and Sandoz strike deal covering up to 5 more biosimilar assets
  • 2026-02-05FY2025 record earnings: revenue KRW 4.1625T, operating profit KRW 1.1685T
  • 2025-12-02OMLYCLO 300mg presentation FDA-approved
  • 2025-04Amgen v Celltrion denosumab patent suit closed via consent judgment
  • 2025-03-10OMLYCLO becomes first interchangeable Xolair biosimilar, FDA-approved
  • 2025-03-03STOBOCLO and OSENVELT denosumab biosimilars FDA-approved
  • 2023-12-28Merger of Celltrion, Inc. and Celltrion Healthcare completed
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources